Literature DB >> 12764551

Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study.

Alexander Drzezga1, Nicola Lautenschlager, Hartwig Siebner, Matthias Riemenschneider, Frode Willoch, Satoshi Minoshima, Markus Schwaiger, Alexander Kurz.   

Abstract

A high percentage of patients with mild cognitive impairment (MCI) develop clinical dementia of the Alzheimer type (AD) within 1 year. The aim of this longitudinal study was to identify characteristic patterns of cerebral metabolism at baseline in patients converting from MCI to AD, and to evaluate the changes in these patterns over time. Baseline and follow-up examinations after 1 year were performed in 22 MCI patients (12 males, 10 females, aged 69.8+/-5.8 years); these examinations included neuropsychological testing, structural cranial magnetic resonance imaging and fluorine-18 fluorodeoxyglucose positron emission tomography (PET) evaluation of relative cerebral glucose metabolic rate (rCMRglc). Individual PET scans were stereotactically normalised with NEUROSTAT software (Univ. of Michigan, Ann Arbor, USA). Subsequently, statistical comparison of PET data with an age-matched healthy control population and between patient subgroups was performed using SPM 99 (Wellcome Dept. of Neuroimaging Sciences, London, UK). After 1 year, eight patients (36%) had developed probable AD (referred to as MCI(AD)), whereas 12 (55%) were still classified as having stable MCI (referred to as MCI(MCI)). Compared with the healthy control group, a reduced rCMRglc in AD-typical regions, including the temporoparietal and posterior cingulate cortex, was detected at baseline in patients with MCI(AD). Abnormalities in the posterior cingulate cortex reached significance even in comparison with the MCI(MCI) group. After 1 year, MCI(AD) patients demonstrated an additional bilateral reduction of rCMRglc in prefrontal areas, along with a further progression of the abnormalities in the parietal and posterior cingulate cortex. No such changes were observed in the MCI(MCI) group. In patients with MCI, characteristic cerebral metabolic differences can be delineated at the time of initial presentation, which helps to define prognostic subgroups. A newly emerging reduction of rCMRglc in prefrontal cortical areas is associated with the transition from MCI to AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12764551     DOI: 10.1007/s00259-003-1194-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  29 in total

Review 1.  Neuroimaging for diagnosis of dementia.

Authors:  G W Small; F Leiter
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

2.  Cognitive process in preclinical phase of dementia.

Authors:  C Fabrigoule; I Rouch; A Taberly; L Letenneur; D Commenges; J M Mazaux; J M Orgogozo; J F Dartigues
Journal:  Brain       Date:  1998-01       Impact factor: 13.501

3.  Selective preservation and degeneration within the prefrontal cortex in aging and Alzheimer disease.

Authors:  D H Salat; J A Kaye; J S Janowsky
Journal:  Arch Neurol       Date:  2001-09

4.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery.

Authors:  K A Welsh; N Butters; R C Mohs; D Beekly; S Edland; G Fillenbaum; A Heyman
Journal:  Neurology       Date:  1994-04       Impact factor: 9.910

5.  Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT.

Authors:  D Kogure; H Matsuda; T Ohnishi; T Asada; M Uno; T Kunihiro; S Nakano; M Takasaki
Journal:  J Nucl Med       Date:  2000-07       Impact factor: 10.057

6.  Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains.

Authors:  K Ishii; F Willoch; S Minoshima; A Drzezga; E P Ficaro; D J Cross; D E Kuhl; M Schwaiger
Journal:  J Nucl Med       Date:  2001-04       Impact factor: 10.057

7.  Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

Authors:  G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

8.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.

Authors:  J C Morris; A Heyman; R C Mohs; J P Hughes; G van Belle; G Fillenbaum; E D Mellits; C Clark
Journal:  Neurology       Date:  1989-09       Impact factor: 9.910

9.  Anatomic standardization: linear scaling and nonlinear warping of functional brain images.

Authors:  S Minoshima; R A Koeppe; K A Frey; D E Kuhl
Journal:  J Nucl Med       Date:  1994-09       Impact factor: 10.057

10.  Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: A clinical validation of statistical parametric mapping.

Authors:  M Signorini; E Paulesu; K Friston; D Perani; A Colleluori; G Lucignani; F Grassi; V Bettinardi; R S Frackowiak; F Fazio
Journal:  Neuroimage       Date:  1999-01       Impact factor: 6.556

View more
  196 in total

Review 1.  Patterns of compensation and vulnerability in normal subjects at risk of Alzheimer's disease.

Authors:  Oscar L Lopez; James T Becker; Lewis H Kuller
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

2.  The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes.

Authors:  Laurel A Beckett; Danielle J Harvey; Anthony Gamst; Michael Donohue; John Kornak; Hao Zhang; Julie H Kuo
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

Review 3.  Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.

Authors:  John Q Trojanowski; Hugo Vandeerstichele; Magdalena Korecka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Z Potter; Michael W Weiner; Clifford R Jack; William Jagust; Arthur W Toga; Virginia M-Y Lee; Leslie M Shaw
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

Review 4.  The concept of FDG-PET endophenotype in Alzheimer's disease.

Authors:  Emmanuel H During; R S Osorio; F M Elahi; L Mosconi; M J de Leon
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

5.  Maternal age affects brain metabolism in adult children of mothers affected by Alzheimer's disease.

Authors:  Lisa Mosconi; Wai Tsui; John Murray; Pauline McHugh; Yi Li; Schantel Williams; Elizabeth Pirraglia; Lidia Glodzik; Susan De Santi; Shankar Vallabhajosula; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2011-04-22       Impact factor: 4.673

6.  Sensory evoked and event related oscillations in Alzheimer's disease: a short review.

Authors:  Görsev G Yener; Erol Başar
Journal:  Cogn Neurodyn       Date:  2010-10-21       Impact factor: 5.082

Review 7.  Positron emission tomography imaging in neurological disorders.

Authors:  Marios Politis; Paola Piccini
Journal:  J Neurol       Date:  2012-09       Impact factor: 4.849

Review 8.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

9.  Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment.

Authors:  A Caroli; C Testa; C Geroldi; F Nobili; L R Barnden; U P Guerra; M Bonetti; G B Frisoni
Journal:  J Neurol       Date:  2007-11-09       Impact factor: 4.849

Review 10.  Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.

Authors:  Lisa Mosconi; Alberto Pupi; Mony J De Leon
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.